Skip to main content
Top
Published in: Cancer Causes & Control 5/2019

01-05-2019 | Breast Cancer | Brief report

Diabetes and differences in detection of incident invasive breast cancer

Authors: Gregory S. Calip, Onchee Yu, Denise M. Boudreau, Huibo Shao, Ruth Oratz, Stephen B. Richardson, Heather T. Gold

Published in: Cancer Causes & Control | Issue 5/2019

Login to get access

Abstract

Many women diagnosed with breast cancer have chronic conditions such as diabetes that may impact other health behaviors. Our purpose was to determine if breast cancer screening and detection differs among women with and without diabetes. We conducted a cross-sectional analysis of a retrospective cohort of women aged 52–74 years diagnosed with incident stages I–III breast cancer enrolled in an integrated health plan between 1999 and 2014 with linkage to the Surveillance, Epidemiology and End Results registry (n = 2040). Screening data were taken from electronic health records. We used multivariable modified Poisson regression models with robust standard errors to estimate relative risks (RR) and 95% confidence intervals (CI) for outcomes of (i) receipt of screening in the 2 years prior to diagnosis; (ii) symptom-detected breast cancer; and (iii) diagnosis of locally advanced stage III breast cancer. Compared to women without diabetes, women with diabetes were similar with respect to receipt of screening mammography (78% and 77%), symptom-detected breast cancer (46% and 49%), and stage III diagnosis (7% and 7%). In multivariable models adjusting for age and year of diagnosis, race, BMI, Charlson comorbidity score and depression diagnosis no differences were observed in the outcomes by presence of diabetes. Further investigation is warranted to determine how diabetes acts as a mediating factor in adverse breast cancer outcomes.
Appendix
Available only for authorised users
Literature
1.
go back to reference American Cancer Society (2015) Breast Cancer Facts & Figures 2015-2016. American Cancer Society, Atlanta American Cancer Society (2015) Breast Cancer Facts & Figures 2015-2016. American Cancer Society, Atlanta
6.
go back to reference Institute of Medicine (U.S.), Committee on Quality of Health Care in America (2013) In: Levit L, Balogh E, Nass S, Ganz PA (eds) Delivering high-quality cancer care: charting a new course for a system in crisis. Institute of Medicine, Washington (DC) Institute of Medicine (U.S.), Committee on Quality of Health Care in America (2013) In: Levit L, Balogh E, Nass S, Ganz PA (eds) Delivering high-quality cancer care: charting a new course for a system in crisis. Institute of Medicine, Washington (DC)
7.
go back to reference Beckman TJ, Cuddihy RM, Scheitel SM, Naessens JM, Killian JM, Pankratz VS (2001) Screening mammogram utilization in women with diabetes. Diabetes Care 24(12):2049–2053CrossRefPubMed Beckman TJ, Cuddihy RM, Scheitel SM, Naessens JM, Killian JM, Pankratz VS (2001) Screening mammogram utilization in women with diabetes. Diabetes Care 24(12):2049–2053CrossRefPubMed
9.
go back to reference Tabaei BP, Herman WH, Jabarin AF, Kim C (2005) Does diabetes care compete with the provision of women’s preventive care services? Diabetes Care 28(11):2644–2649CrossRefPubMed Tabaei BP, Herman WH, Jabarin AF, Kim C (2005) Does diabetes care compete with the provision of women’s preventive care services? Diabetes Care 28(11):2644–2649CrossRefPubMed
11.
go back to reference Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD (2009) Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8(6):909–915CrossRefPubMed Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD (2009) Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8(6):909–915CrossRefPubMed
13.
go back to reference Bronsveld HK, ter Braak B, Karlstad O, Vestergaard P, Starup-Linde J, Bazelier MT, De Bruin ML, de Boer A, Siezen CL, van de Water B, Siezen CL, van de Laan JW, Schmidt MK (2015) Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Res 17:100. https://doi.org/10.1186/s13058-015-0611-2 CrossRefPubMedPubMedCentral Bronsveld HK, ter Braak B, Karlstad O, Vestergaard P, Starup-Linde J, Bazelier MT, De Bruin ML, de Boer A, Siezen CL, van de Water B, Siezen CL, van de Laan JW, Schmidt MK (2015) Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Res 17:100. https://​doi.​org/​10.​1186/​s13058-015-0611-2 CrossRefPubMedPubMedCentral
20.
go back to reference Saunders KW, Davis RL, Stergachis A (2005) Group health cooperative. In: Strom BL (ed) Pharmacoepidemiology, 4th edn. Wiley, Hoboken, pp 223–239 Saunders KW, Davis RL, Stergachis A (2005) Group health cooperative. In: Strom BL (ed) Pharmacoepidemiology, 4th edn. Wiley, Hoboken, pp 223–239
21.
go back to reference Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, Habel LA, Yood MU, McCarty C, Magid DJ, Wagner EH, Pharmacovigilance Study T (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104(17):1293–1305CrossRefPubMedPubMedCentral Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, Habel LA, Yood MU, McCarty C, Magid DJ, Wagner EH, Pharmacovigilance Study T (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104(17):1293–1305CrossRefPubMedPubMedCentral
24.
go back to reference Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613–619CrossRefPubMed Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613–619CrossRefPubMed
25.
go back to reference Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL (2003) Staging system for breast cancer: revisions for the 6th edition of the AJCC cancer staging manual. Surg Clin North Am 83(4):803–819CrossRefPubMed Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL (2003) Staging system for breast cancer: revisions for the 6th edition of the AJCC cancer staging manual. Surg Clin North Am 83(4):803–819CrossRefPubMed
26.
go back to reference Zou G (2004) A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159(7):702–706CrossRefPubMed Zou G (2004) A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159(7):702–706CrossRefPubMed
31.
go back to reference Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB (2012) Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care 18(11):721–726PubMed Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB (2012) Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care 18(11):721–726PubMed
Metadata
Title
Diabetes and differences in detection of incident invasive breast cancer
Authors
Gregory S. Calip
Onchee Yu
Denise M. Boudreau
Huibo Shao
Ruth Oratz
Stephen B. Richardson
Heather T. Gold
Publication date
01-05-2019
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 5/2019
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-019-01166-2

Other articles of this Issue 5/2019

Cancer Causes & Control 5/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine